A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
AstraZeneca
Astellas Pharma Inc
Parabilis Medicines, Inc.
Ruijin Hospital
Dana-Farber Cancer Institute
Fudan University
I-Mab Biopharma US Limited
University Hospital, Akershus
Duke University